CEO of @truemed @jwmares on effect of GLP-1s on the American consumer: "The oral version of Ozempic is coming this year. There will be 50 million Americans on these in the next five years." "I think there's going to be a backlash where people start to see downsides... that just come from - even if you're eating a bad diet, but you're eating less of it, you're still going to have health problems. Even if you may be less overweight, or less obese than you were previously."